Clear cell acanthoma

Summary

Clear cell acanthoma (MONDO:0002086) is a disease. A subtype of acanthoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	clear cell acanthoma
Mondo ID	MONDO:0002086
DOID	DOID:172
ICD-11	1582724858
NCIT	C97041
SNOMED CT	254670002
UMLS	C0333992
MedGen	83098
Is cancer (heuristic)	no

Also known as: clear cell acanthoma (morphologic abnormality) · Degos acanthoma · pale (clear cell) acanthoma

Disease family

This is a subtype of acanthoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › integumentary system benign neoplasm › benign neoplasm of skin › benign epithelial skin neoplasm › acanthoma › clear cell acanthoma

Related subtypes (5): large cell acanthoma, epidermolytic acanthoma, acantholytic acanthoma, pilar sheath acanthoma, warty dyskeratoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.